A detailed history of Carnegie Capital Asset Management, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Carnegie Capital Asset Management, LLC holds 32,242 shares of BMY stock, worth $1.9 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
32,242
Previous 33,539 3.87%
Holding current value
$1.9 Million
Previous $1.39 Million 19.83%
% of portfolio
0.05%
Previous 0.04%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 10, 2024

SELL
$39.66 - $51.75 $51,439 - $67,119
-1,297 Reduced 3.87%
32,242 $1.67 Million
Q2 2024

Jul 19, 2024

SELL
$40.25 - $52.99 $761,006 - $1 Million
-18,907 Reduced 36.05%
33,539 $1.39 Million
Q1 2024

May 03, 2024

SELL
$47.98 - $54.4 $1.23 Million - $1.4 Million
-25,730 Reduced 32.91%
52,446 $2.84 Million
Q4 2023

Jan 29, 2024

SELL
$48.48 - $57.85 $839,140 - $1 Million
-17,309 Reduced 18.13%
78,176 $4.01 Million
Q3 2023

Oct 10, 2023

SELL
$57.89 - $64.73 $136,851 - $153,021
-2,364 Reduced 2.42%
95,485 $5.54 Million
Q2 2023

Aug 04, 2023

SELL
$63.71 - $70.74 $1.4 Million - $1.55 Million
-21,956 Reduced 18.33%
97,849 $6.26 Million
Q1 2023

Apr 19, 2023

BUY
$65.71 - $74.53 $673,856 - $764,305
10,255 Added 9.36%
119,805 $8.3 Million
Q4 2022

Jan 23, 2023

BUY
$68.48 - $81.09 $12,805 - $15,163
187 Added 0.17%
109,550 $0
Q3 2022

Oct 13, 2022

BUY
$0.13 - $76.84 $2,142 - $1.27 Million
16,477 Added 17.74%
109,363 $7.78 Million
Q2 2022

Aug 02, 2022

BUY
$72.62 - $79.98 $174,288 - $191,952
2,400 Added 2.65%
92,886 $7.15 Million
Q2 2022

Jul 13, 2022

SELL
$72.62 - $79.98 $486,045 - $535,306
-6,693 Reduced 6.89%
90,486 $6.05 Million
Q1 2022

Apr 11, 2022

SELL
$61.48 - $73.72 $23,423 - $28,087
-381 Reduced 0.39%
97,179 $7.1 Million
Q4 2021

Jan 21, 2022

SELL
$53.63 - $62.52 $305,851 - $356,551
-5,703 Reduced 5.52%
97,560 $6.08 Million
Q3 2021

Oct 08, 2021

BUY
$59.17 - $69.31 $756,015 - $885,573
12,777 Added 14.12%
103,263 $6.11 Million
Q2 2021

Jul 16, 2021

BUY
$61.91 - $67.42 $1.07 Million - $1.16 Million
17,241 Added 23.54%
90,486 $6.05 Million
Q1 2021

Apr 12, 2021

BUY
$59.34 - $66.74 $658,080 - $740,146
11,090 Added 17.84%
73,245 $4.63 Million
Q4 2020

Feb 08, 2021

SELL
$57.74 - $65.43 $61,608 - $69,813
-1,067 Reduced 1.69%
62,155 $3.86 Million
Q3 2020

Oct 13, 2020

SELL
$57.43 - $63.64 $152,017 - $168,455
-2,647 Reduced 4.02%
63,222 $3.81 Million
Q2 2020

Jul 09, 2020

BUY
$54.82 - $64.09 $3,947 - $4,614
72 Added 0.11%
65,869 $3.87 Million
Q1 2020

May 08, 2020

SELL
$46.4 - $67.43 $125,883 - $182,937
-2,713 Reduced 3.96%
65,797 $3.65 Million
Q4 2019

Feb 13, 2020

BUY
$49.21 - $64.19 $82,672 - $107,839
1,680 Added 2.51%
68,510 $4.4 Million
Q3 2019

Nov 20, 2019

SELL
$42.77 - $50.71 $11,291 - $13,387
-264 Reduced 0.39%
66,830 $3.39 Million
Q2 2019

Jul 24, 2019

SELL
$44.62 - $49.34 $769,695 - $851,115
-17,250 Reduced 20.45%
67,094 $3.04 Million
Q1 2019

May 14, 2019

BUY
$45.12 - $53.8 $179,261 - $213,747
3,973 Added 4.94%
84,344 $4.02 Million
Q4 2018

Feb 14, 2019

SELL
$48.76 - $63.23 $3.18 Million - $4.12 Million
-65,204 Reduced 44.79%
80,371 $4.18 Million
Q3 2018

Nov 27, 2018

BUY
$55.19 - $62.25 $1.24 Million - $1.4 Million
22,461 Added 18.24%
145,575 $7.88 Million
Q2 2018

Aug 16, 2018

BUY
$50.53 - $62.98 $1.03 Million - $1.28 Million
20,400 Added 19.86%
123,114 $7.38 Million
Q1 2018

May 15, 2018

BUY
$59.92 - $68.98 $460,545 - $530,180
7,686 Added 8.09%
102,714 $5.33 Million
Q4 2017

Feb 12, 2018

BUY
$59.94 - $65.35 $643,995 - $702,120
10,744 Added 12.75%
95,028 $5.94 Million
Q3 2017

Nov 14, 2017

BUY
$55.23 - $63.74 $1.83 Million - $2.11 Million
33,110 Added 64.7%
84,284 $5.38 Million
Q2 2017

Aug 14, 2017

BUY
N/A
51,174
51,174 $2.84 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Carnegie Capital Asset Management, LLC Portfolio

Follow Carnegie Capital Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Carnegie Capital Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Carnegie Capital Asset Management, LLC with notifications on news.